Inhibikase Therapeutics (IKT) Earnings Date, Estimates & Call Transcripts → Collapse of the Petrodollar (From Colonial Metals) (Ad) Free IKT Stock Alerts $1.31 -0.05 (-3.68%) (As of 05/10/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Earnings SummaryUpcoming Earnings DateMay. 20EstimatedActual EPS (Mar. 27) -$0.63 Beat By $0.15 Consensus EPS (Mar. 27) -$0.78 Read Call TranscriptListen to Call Get Inhibikase Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for IKT and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueIKT Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.IKT Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Colonial MetalsCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar. For one main reason.In answer to this issue, we have released a Special Report to the public. Inhibikase Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241($0.79)($0.79)($0.79)Q2 20241($0.37)($0.37)($0.37)Q3 20241($0.37)($0.37)($0.37)Q4 20241($0.38)($0.38)($0.38)FY 20244($1.91)($1.91)($1.91)IKT Earnings Date and InformationInhibikase Therapeutics last posted its quarterly earnings results on March 27th, 2024. The reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.15. Inhibikase Therapeutics has generated ($3.56) earnings per share over the last year (($3.56) diluted earnings per share). Earnings for Inhibikase Therapeutics are expected to grow in the coming year, from ($1.71) to ($1.52) per share. Inhibikase Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 20th, 2024 based off prior year's report dates.Read More Inhibikase Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/20/2024Estimated)------- 3/27/2024Q4 2023($0.78)($0.63)+$0.15($0.63)-- 11/14/2023Q3 2023($1.12)($0.86)+$0.26($0.86)-$0.08 million8/14/2023Q2 2023($0.92)($1.11)($0.19)($1.11)-$0.12 million 5/15/2023Q1 2023($0.90)($0.96)($0.06)($0.16)-$0.07 million3/31/2023Q4 2022-($1.02)($1.02)($0.17)-$0.06 million11/14/2022Q3 2022-($1.08)($1.08)($0.18)-$0.01 million Get the Latest News and Ratings for IKT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/12/2022Q2 2022-($1.08)($1.08)($0.18)-$0.01 million5/16/2022Q1 2022-($1.08)($1.08)($0.18)-$0.05 million 3/31/2022Q4 2021-($1.20)($1.20)($0.20)--11/15/2021Q3 2021($0.84)($1.08)($0.24)($0.18)-$0.33 million8/16/2021Q2 2021($2.28)($1.32)+$0.96($0.22)-$1.36 million5/17/2021Q1 2021-($1.56)($1.56)($0.26)-$1.41 million Inhibikase Therapeutics Earnings - Frequently Asked Questions When is Inhibikase Therapeutics's earnings date? Inhibikase Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 20th, 2024 based off last year's report dates. Learn more on IKT's earnings history. Did Inhibikase Therapeutics beat their earnings estimates last quarter? In the previous quarter, Inhibikase Therapeutics (NYSE:IKT) reported ($0.63) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.78) by $0.15. Learn more on analysts' earnings estimate vs. IKT's actual earnings. How can I listen to Inhibikase Therapeutics's earnings conference call? The conference call for Inhibikase Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Inhibikase Therapeutics's conference call transcript? The conference call transcript for Inhibikase Therapeutics's latest earnings report can be read online. Read Transcript How much revenue does Inhibikase Therapeutics generate each year? Inhibikase Therapeutics (NYSE:IKT) has a recorded annual revenue of $260,000.00. How much profit does Inhibikase Therapeutics generate each year? Inhibikase Therapeutics (NYSE:IKT) has a recorded net income of -$19.03 million. IKT has generated -$3.56 earnings per share over the last four quarters. What is Inhibikase Therapeutics's EPS forecast for next year? Inhibikase Therapeutics's earnings are expected to grow from ($1.71) per share to ($1.52) per share in the next year. More Earnings Resources from MarketBeat Related Companies: NSTGQ Earnings Results SRNE Earnings Results ONVO Earnings Results PALI Earnings Results CELZ Earnings Results TTNP Earnings Results BCDA Earnings Results FRTX Earnings Results TCON Earnings Results FNCH Earnings Results Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Traders Sell but Investors Still Win After Palantir's EarningsTech Earnings Insights: Where Opportunity Meets UncertaintyApple’s Earnings Show Investors Its Strength and Its WeaknessCarvana’s Q1 Earnings: A Profitability U-TurnPayPal’s Strong Earnings Growth and Strategic Evolution GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future Outlook This page (NYSE:IKT) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaThe A.I. story nobody is telling you (Read ASAP)TradeSmithA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsDems have chosen Biden replacement?Paradigm PressRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable ProsperityForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.